Clinical Trial Update: Modulation of Vasoreactivity in Septic Shock: Impact of Recombinant Protein C [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating how recombinant protein C modulates vasoreactivity in septic shock has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Septic Shock

Drugs mentioned

• Xigran (drotrecogin alfa activated) (drotrecogin alfa activated)

Snippet

Sponsor: Central Hospital, Nancy, France | Conditions: Septic Shock | Phase 4 | Status: COMPLETED